This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Trifilio, S. M.
Right arrow Articles by Mehta, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Trifilio, S. M.
Right arrow Articles by Mehta, J.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, May 2009, p. 1793-1796, Vol. 53, No. 5
0066-4804/09/$08.00+0     doi:10.1128/AAC.01316-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Serial Plasma Voriconazole Concentrations after Allogeneic Hematopoietic Stem Cell Transplantation{triangledown}

Steven M. Trifilio,1,2 Paul R. Yarnold,3 Marc H. Scheetz,2,4 Judy Pi,1,2 Gennethel Pennick,5 and Jayesh Mehta1,3*

Hematopoietic Stem Cell Transplant Program, Northwestern Memorial Hospital, Chicago, Illinois,1 Department of Pharmacy, Northwestern Memorial Hospital, Chicago, Illinois,2 The Feinberg School of Medicine, The Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, Illinois,3 Department of Pharmacy Practice, Midwestern University Chicago College of Pharmacy, Chicago, Illinois,4 Fungus Testing Laboratory, University of Texas Health Science Center-SA, San Antonio, Texas5

Received 1 October 2008/ Returned for modification 10 December 2008/ Accepted 2 February 2009

Plasma voriconazole concentrations vary considerably between patients receiving standard dosing, and trough voriconazole concentrations are known to affect efficacy and toxicity. Temporal variations in serial plasma voriconazole concentrations through the course of therapy in hematopoietic stem cell transplantation patients has not been carefully described. Paired voriconazole concentrations in 64 patients were studied to determine the predictability of the second concentration based on the first. The difference between the two values was ≤5% in six patients. In 25 patients, the second concentration was higher by a median of 40%. In 33 patients, the subsequent concentration was lower by a median of 59%. For patients with an initial concentration of <2 µg/ml, the correlation between the two values was poor (r = 0.24; P < 0.17). For those with an initial concentration of ≥2 µg/ml, the correlation was good (r = 0.72; P < 0.0001). There was no relationship between the magnitude of the change and the time elapsing between the two measurements. Among the 43 patients who had an initial concentration of ≥1 µg/ml, the two voriconazole measurements were strongly correlated (r = 0.66, P < 0.0001), but only 67% had a voriconazole serum concentration of ≥1 µg/ml on the second measurement. No studied variables were reliable predictors in identifying concentrations above or below 1 or 2 µg/ml. Our data suggest that variations in voriconazole concentrations are unpredictable despite standard dosing, and the acceptability of a concentration on one occasion cannot be extrapolated to future concentrations in the same patient. This suggests that ongoing therapeutic drug monitoring and dose adjustment may be beneficial in patients requiring prolonged voriconazole therapy.


* Corresponding author. Mailing address: 676 N. St. Clair St., Ste. 850, Chicago, IL 60611. Phone: (312) 695-4443. Fax: (321) 695-6189. E-mail: j-mehta{at}northwestern.edu

{triangledown} Published ahead of print on 17 February 2009.


Antimicrobial Agents and Chemotherapy, May 2009, p. 1793-1796, Vol. 53, No. 5
0066-4804/09/$08.00+0     doi:10.1128/AAC.01316-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.